GLP-3 retatrutide explained: triple-agonist mechanism, Phase 3 TRIUMPH data, dysesthesia signal, FDA timeline, and how PlexusDx’s currently-available compounded semaglutide and tirzepatide protocols compare to the pipeline asset.

Disclaimer: The products promoted on this page are intended strictly for laboratory and scientific research use only. They are not approved by the FDA for human consumption, diagnosis, or clinical treatment. Portions of this page contain affiliate links, meaning we earn a commission if you make a purchase through our partner links at no extra cost to you.

The standard FDA tirzepatide dosing schedule moves through six weekly dose levels: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, with at least four weeks between steps. This guide walks the week-by-week ladder for both injection and oral compounded tirzepatide, the milligram-to-unit conversions for compounded vials, missed-dose rules, and how the GIPR rs1800437 genetic variant can inform titration pace before week one.

Retatrutide (Lilly's investigational triple agonist) and orforglipron (Lilly's oral non-peptide GLP-1) are the two big pipeline stories in 2026 — but neither is FDA-approved yet. Here's the realistic timeline, the Phase 3 data, the announced and unknown pricing, and how PlexusDx's currently-available compounded semaglutide and tirzepatide protocols ($129/mo to $349/mo) compare for someone who needs an option today rather than in 2028.

Disclaimer: The products promoted on this page are intended strictly for laboratory and scientific research use only. They are not approved by the FDA for human consumption, diagnosis, or clinical treatment. Portions of this page contain affiliate links, meaning we earn a commission if you make a purchase through our partner links at no extra cost to you.

Foundayo's $149 headline is a one-month starter price — the real cash-pay year runs $3,338–$3,738 once you escalate. Compare PlexusDx Microdose GLP-1 ($129/mo flat), Semaglutide Oral ($289/mo), and Tirzepatide Oral ($349/mo) on annualized cost.

Foundayo costs $25/month with covered commercial insurance, $50/month on the Medicare GLP-1 Bridge, or $149-$289/mo self-pay through LillyDirect. Most commercial plans don't cover GLP-1s for weight loss in 2026. Compare cash-pay PlexusDx Weight Management Protocols — Microdose at $129/mo flat, Semaglutide Injection $189/mo, Tirzepatide Injection $289/mo — with no membership fee.